ClinicalTrials.gg
TerminatedNCT00758966Updated Nov 29, 2012

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

A Phase 2 interventional study of Fluoxetine 60 mg and Naltrexone 32 mg and fluoxetine 60 mg in Obsessive-Compulsive Disorder, sponsored by Orexigen Therapeutics, Inc. Terminated at 11 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2012-11-29.

Sponsored by Orexigen Therapeutics, Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision- Financial Considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Obsessive-Compulsive Disorder with a site in United States — 59 open to participants now, 77 under way, 2 of them phase 3. Obsessive-Compulsive Disorder · United States.

Enrollment
215th of 246
8 · median 40
Started
2008
with 10 others
Phase 2
46 of 299
6 open now
Registered
60th of 299
by date

Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, this one is the 215th largest by enrollment of the 246 interventional ones that give a count, is one of 11 that started in 2008, is one of 46 in phase 2, and was the 60th registered.

Obsessive-Compulsive Disorder

636 studies on the registry are indexed under Obsessive-Compulsive Disorder; 166 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

59 of the 299 studies in Obsessive-Compulsive Disorder with a site in United States are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 119 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 81 (68%) stop at 75 or younger; 28 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Obsessive-Compulsive Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either fluoxetine alone or naltrexone SR alone.

03

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • OCD,
  • naltrexone,
  • fluoxetine,
  • obsessive-compulsive disorder
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, 18 to 60 years of age (inclusive)
  • Outpatients with a current diagnosis of OCD that have received previous therapy
  • Negative serum pregnancy test as screening in women of
  • If a woman of child-bearing potential, must agreed to use an acceptable and effective form of
  • No abnormality on (ECG)
  • No clinically significant laboratory abnormality at screening
  • Negative urine drug screen
  • Must be considered reliable and possess a level of understanding that enables the subject to provide written and to comply with protocol procedures and schedule

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of substance dependence
  • Diagnosis of substance abuse (except for nicotine and caffeine)
  • Serious or unstable medical illnesses
  • Lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, anorexia nervosa, Pervasive Developmental Disorder (PDD), Asperger's Syndrome or the presence of antisocial or borderline personality disorder
  • Diagnosis of tic disorder or Tourette's Syndrome
  • Subjects diagnosed with impulse control disorder
  • Known sensitivity or allergic reaction to either naltrexone or fluoxetine
  • Any condition which in the opinion of the investigator or Sponsor makes the subject unsuitable for inclusion in the study
  • Immediate family of investigators, study personnel or Sponsor representatives
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    NF (Naltrexone+Fluoxetine)

    Naltrexone SR 32 mg and fluoxetine 60 mg

    Drug: Naltrexone 32 mg and fluoxetine 60 mg

  • Active comparator
    Fluoxetine

    Fluoxetine 60 mg

    Drug: Fluoxetine 60 mg

  • Active comparator
    Naltrexone

    Naltrexone SR 32 mg

    Drug: Naltrexone SR 32 mg

Interventions

  • Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.

  • DrugNaltrexone 32 mg and fluoxetine 60 mg

    Drug page: Naltrexone

    Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.

  • Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.

06

What researchers measure

Primary outcomes

  1. Evaluate the mean change from baseline to Week 10 in total Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score between the combination treatment group versus fluoxetine alone and naltrexone SR alone

    Time frame: Baseline to Week 10

07

Study locations

11 sites
  • Synergy Clinical Research
    National City, California 91950, United States
  • California Clinical Trials
    San Diego, California 92123, United States
  • University of Florida, Department of Psychiatry
    Gainesville, Florida 32606, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Global Medical Institute, LLC
    Princeton, New Jersey 08540, United States
  • Brooklyn Medical Institute
    Brooklyn, New York 11223, United States
  • Community Research
    Cincinnati, Ohio 45227, United States
  • Summit Research Network, Inc.
    Portland, Oregon 97210, United States
  • Carolina Clinical Research Services
    Columbia, South Carolina 29201, United States
  • Northbrooke Research Center
    Brown Deer, Wisconsin 53223, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2008
First posted
Sep 25, 2008
Start
Sep 2008
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results delay requested
Nov 27, 2012
Last update
Nov 29, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00758966
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
Sep 25, 2008
Start date
Sep 2008
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Nov 29, 2012

Study contacts

Jeffrey T Apter, MD, PA
principal investigator · Global Medical Institutes, LLC
Ward Smith, MD
principal investigator · Summit Research Network, Inc.
Vishaal Mehra, MD
principal investigator · California Clinical Trials
Naresh P Emmanuel, MD
principal investigator · Carolina Clinical Research Services
Mohammad Bari, MD
principal investigator · Synergy Clinical Research
Robert Riesenberg, MD
principal investigator · Atlanta Center for Medical Research
Teresa Pigott, MD
principal investigator · University of Florida, Dept Of Psychiatry
Andrew W Goddard, MD
principal investigator · Indiana University School of Medicine
Al Rivera, MD
principal investigator · Community Research
Jeffrey S Simon, MD
principal investigator · Northbrooke Research Center
Zinoviy Benzar, MD
principal investigator · Brooklyn Medical Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion